Onctura has dosed the first subject in the open-label Phase II OCULE-01 trial of oral roginolisib in individuals with rare ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Esperion Therapeutics ESPR announced that it has come to an alignment with the FDA for initiating two phase III studies. The ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...

As previously reported, the LYNX-1 Phase 3 study met its primary endpoint, with a statistically significant greater percentage of Phentolamine Ophthalmic Solution 0.75%-treated participants gaining 15 ...

Shares of Pacira BioSciences PCRX have surged 66.8% in the past six months against the industry’s decline of 8.7%. The stock has also outperformed the sector and the S&P 500 index during this ...

Biofrontera Inc. reports a record $37.3M in 2024 revenue, FDA milestones, and strategic growth plans for 2025.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts spotted several shortfalls in the drug's label, leaving more to be desired—and ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...